ClinicalTrials.gg
CompletedNCT01133496Updated Jun 14, 2010

Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions

A Phase 1 interventional study of Alendronate Sodium Tablets, 70 mg in Healthy, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-06-14.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to determine the bioequivalence of Alendronate Sodium 70 mg of Dr. Reddy's and Fosamax Tablets 70 mg of Merck \& Co.

Read the detailed description

Open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose, crossover oral bioequivalence study of Alendronate sodium 70 mg tablets of Dr Reddy's Laboratories Limited, India and Fosamax® tablets of Merck \& Co., Inc., USA, in healthy, adult, human subjects under fasting conditions.

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Alendronate Sodium
  • crossover
03

In context

Lead sponsor

Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy human subjects aged between 18 and 45 years (including both).
  2. Subjects with a between 18.5 - 24.9 Kg/m2 but weight not less than 45 Kgs.
  3. Female subjects who are or surgically sterile.
  4. Female subjects of child bearing potential practicing an acceptable method of for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD) or abstinence.
  5. Subjects with normal health as determined by personal medical history, clinical examination, and laboratory examinations and serology tests.
  6. Subjects having normal 12-lead (ECG).
  7. Subjects having normal chest X-Ray (P/A view).
  8. Subjects able to communicate effectively.
  9. Subjects willing to given written and adhere to all the requirements of this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subjects having or to Alendronate sodium or related drugs.
  2. History or presence of any medical condition or disease according the opinion of the physician.
  3. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
  4. History or presence of significant alcoholism or drug abuse in the past one year.
  5. History or presence of significant smoking (more than 10 cigarettes or beedi's/day or consumption of tobacco products).
  6. Difficulty with donating blood.
  7. Difficulty in swallowing solids like tablets or capsules.
  8. Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg.
  9. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.
  10. Pulse rate less than 50/minute or more than 100/minute.
  11. Use of any prescribed medication during last two weeks or OTC medical products during the last one week preceding the first dosing.
  12. Major illness during 3 months before screening.
  13. Participation in a drug research study within past 3 months.
  14. Donation of blood in the past 3 months before screening.
  15. Female volunteers demonstrating a positive pregnancy screen.
  16. Female volunteers who are currently breast-feeding.
  17. Female volunteers with child bearing potential using prohibited method (Oral, Injectable or Implantable hormonal agents).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Alendronate Sodium

    Alendronate Sodium Tablets, 70 mg of Dr. Reddy's

    Drug: Alendronate Sodium Tablets, 70 mg

  • Active comparator
    Fosamax

    Fosamax Tablets 70 mg of Merck \& Company. Inc., USA.

    Drug: Alendronate Sodium Tablets, 70 mg

Interventions

  • DrugAlendronate Sodium Tablets, 70 mg

    Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.

    Also known as: Fosamax Tablets 70 mg

06

What researchers measure

Primary outcomes

  1. Bioequivalence based on Cmax and AUC parameters

    Time frame: 5 months

07

Study locations

1 site
  • GVK Biosciences Pvt. Ltd.,
    Hyderabad, Andhra Pradesh 500038, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Dec 2006 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2010
First posted
May 28, 2010
Start
Dec 2006
Primary completionActual
Dec 2006
CompletionActual
Apr 2007
Last update
Jun 14, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01133496
First posted
May 28, 2010
Start date
Dec 2006
Primary completion
Dec 2006
Completion
Apr 2007
Last update
Jun 14, 2010

Study contacts

Dr. Naba Kr Talukdar, MD
principal investigator · GVK Biosciences Pvt. Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion